Logo image of HYPR

HYPERFINE INC (HYPR) Stock Fundamental Analysis

NASDAQ:HYPR - Nasdaq - US44916K1060 - Common Stock - Currency: USD

0.757  -0.02 (-2.47%)

Fundamental Rating

3

Taking everything into account, HYPR scores 3 out of 10 in our fundamental rating. HYPR was compared to 191 industry peers in the Health Care Equipment & Supplies industry. While HYPR has a great health rating, there are worries on its profitability. While showing a medium growth rate, HYPR is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year HYPR has reported negative net income.
In the past year HYPR has reported a negative cash flow from operations.
In the past 5 years HYPR always reported negative net income.
HYPR had a negative operating cash flow in each of the past 5 years.
HYPR Yearly Net Income VS EBIT VS OCF VS FCFHYPR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 -20M -40M -60M

1.2 Ratios

HYPR has a Return On Assets of -69.13%. This is in the lower half of the industry: HYPR underperforms 74.35% of its industry peers.
With a Return On Equity value of -83.03%, HYPR is not doing good in the industry: 60.21% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -69.13%
ROE -83.03%
ROIC N/A
ROA(3y)-56.89%
ROA(5y)-47.09%
ROE(3y)-64.86%
ROE(5y)-52.85%
ROIC(3y)N/A
ROIC(5y)N/A
HYPR Yearly ROA, ROE, ROICHYPR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 -20 -40 -60 -80

1.3 Margins

HYPR has a Gross Margin of 45.70%. This is in the lower half of the industry: HYPR underperforms 62.30% of its industry peers.
HYPR does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 45.7%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
HYPR Yearly Profit, Operating, Gross MarginsHYPR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 2024 0 -2K -4K -6K

More info and screens

7

2. Health

2.1 Basic Checks

HYPR does not have a ROIC to compare to the WACC, probably because it is not profitable.
HYPR has more shares outstanding than it did 1 year ago.
HYPR has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
HYPR Yearly Shares OutstandingHYPR Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 20M 40M 60M
HYPR Yearly Total Debt VS Total AssetsHYPR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 50M 100M 150M 200M

2.2 Solvency

Based on the Altman-Z score of -4.61, we must say that HYPR is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of HYPR (-4.61) is worse than 65.44% of its industry peers.
HYPR has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -4.61
ROIC/WACCN/A
WACC9.07%
HYPR Yearly LT Debt VS Equity VS FCFHYPR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 0 50M -50M 100M 150M

2.3 Liquidity

A Current Ratio of 6.15 indicates that HYPR has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 6.15, HYPR belongs to the top of the industry, outperforming 84.29% of the companies in the same industry.
A Quick Ratio of 5.48 indicates that HYPR has no problem at all paying its short term obligations.
HYPR has a better Quick ratio (5.48) than 83.77% of its industry peers.
Industry RankSector Rank
Current Ratio 6.15
Quick Ratio 5.48
HYPR Yearly Current Assets VS Current LiabilitesHYPR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 50M 100M 150M

More info and screens

6

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 9.68% over the past year.
The Revenue has grown by 16.84% in the past year. This is quite good.
HYPR shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 105.01% yearly.
EPS 1Y (TTM)9.68%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%6.67%
Revenue 1Y (TTM)16.84%
Revenue growth 3Y105.01%
Revenue growth 5YN/A
Sales Q2Q%-13.59%

3.2 Future

HYPR is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 8.04% yearly.
The Revenue is expected to grow by 16.76% on average over the next years. This is quite good.
EPS Next Y18.49%
EPS Next 2Y11.95%
EPS Next 3Y9.1%
EPS Next 5Y8.04%
Revenue Next Year15.64%
Revenue Next 2Y22%
Revenue Next 3Y18.81%
Revenue Next 5Y16.76%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
HYPR Yearly Revenue VS EstimatesHYPR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 5M 10M 15M 20M 25M
HYPR Yearly EPS VS EstimatesHYPR Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 2026 2027 2028 2029 -0.2 -0.4 -0.6 -0.8 -1

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for HYPR. In the last year negative earnings were reported.
Also next year HYPR is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
HYPR Price Earnings VS Forward Price EarningsHYPR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
HYPR Per share dataHYPR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 0.4 -0.4 0.6

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y11.95%
EPS Next 3Y9.1%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for HYPR!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

HYPERFINE INC

NASDAQ:HYPR (4/25/2025, 8:13:47 PM)

0.757

-0.02 (-2.47%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)03-17 2025-03-17/amc
Earnings (Next)05-08 2025-05-08
Inst Owners22.77%
Inst Owner Change0.06%
Ins Owners4.28%
Ins Owner Change-0.4%
Market Cap58.92M
Analysts78
Price Target1.32 (74.37%)
Short Float %4.14%
Short Ratio1.88
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)0.15%
Min EPS beat(2)-1.67%
Max EPS beat(2)1.96%
EPS beat(4)3
Avg EPS beat(4)2.17%
Min EPS beat(4)-1.67%
Max EPS beat(4)6.42%
EPS beat(8)6
Avg EPS beat(8)2.22%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-7.91%
Min Revenue beat(2)-24.15%
Max Revenue beat(2)8.33%
Revenue beat(4)3
Avg Revenue beat(4)-0.24%
Min Revenue beat(4)-24.15%
Max Revenue beat(4)9.07%
Revenue beat(8)4
Avg Revenue beat(8)-4.32%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-2.44%
PT rev (3m)5.21%
EPS NQ rev (1m)16.07%
EPS NQ rev (3m)9.62%
EPS NY rev (1m)8.67%
EPS NY rev (3m)20.09%
Revenue NQ rev (1m)-9.2%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)1.09%
Revenue NY rev (3m)-15.3%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 4.57
P/FCF N/A
P/OCF N/A
P/B 1.2
P/tB 1.2
EV/EBITDA N/A
EPS(TTM)-0.56
EYN/A
EPS(NY)-0.46
Fwd EYN/A
FCF(TTM)-0.5
FCFYN/A
OCF(TTM)-0.5
OCFYN/A
SpS0.17
BVpS0.63
TBVpS0.63
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -69.13%
ROE -83.03%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 45.7%
FCFM N/A
ROA(3y)-56.89%
ROA(5y)-47.09%
ROE(3y)-64.86%
ROE(5y)-52.85%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.22
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 37.96%
Cap/Sales 2.97%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 6.15
Quick Ratio 5.48
Altman-Z -4.61
F-Score4
WACC9.07%
ROIC/WACCN/A
Cap/Depr(3y)57.29%
Cap/Depr(5y)217.57%
Cap/Sales(3y)6.28%
Cap/Sales(5y)146.68%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)9.68%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%6.67%
EPS Next Y18.49%
EPS Next 2Y11.95%
EPS Next 3Y9.1%
EPS Next 5Y8.04%
Revenue 1Y (TTM)16.84%
Revenue growth 3Y105.01%
Revenue growth 5YN/A
Sales Q2Q%-13.59%
Revenue Next Year15.64%
Revenue Next 2Y22%
Revenue Next 3Y18.81%
Revenue Next 5Y16.76%
EBIT growth 1Y10.17%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year20.11%
EBIT Next 3Y8.53%
EBIT Next 5YN/A
FCF growth 1Y8.13%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y7.28%
OCF growth 3YN/A
OCF growth 5YN/A